Information:
Fel:
ID
13160
Beskrivning
Study of Troxatyl™ Administered by Continuous Infusion to Subjects With Refractory Acute Myelogenous Leukemia (AML); ODM derived from: https://clinicaltrials.gov/show/NCT00104468
Länk
https://clinicaltrials.gov/show/NCT00104468
Nyckelord
Versioner (1)
- 2016-01-20 2016-01-20 -
Rättsinnehavare
CC BY-NC 3.0
Uppladdad den
20 januari 2016
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Acute Myelogenous Leukemia NCT00104468
Eligibility Acute Myelogenous Leukemia NCT00104468
- StudyEvent: Eligibility
Similar models
Eligibility Acute Myelogenous Leukemia NCT00104468
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
AML
Item
confirmed diagnosis of acute myelogenous leukemia (aml) refractory to prior therapy and/or unlikely to benefit from known therapies.
boolean
C0023467 (UMLS CUI [1])
organ and immune function
Item
subjects must have adequate organ and immune function as indicated by the following laboratory values: *creatinine clearance ≥5 l/hr (83ml/min), *total bilirubin ≤2.0 mg/dl (≤34.2 µmol/l), *ast(sgot) and alt(sgpt) ≤3 x uln
boolean
C0373595 (UMLS CUI [1])
C1278039 (UMLS CUI [2])
C0201899 (UMLS CUI [3])
C0201836 (UMLS CUI [4])
C1278039 (UMLS CUI [2])
C0201899 (UMLS CUI [3])
C0201836 (UMLS CUI [4])
cns leukemia
Item
clinical evidence of active central nervous system (cns) leukemic involvement
boolean
C1332884 (UMLS CUI [1])
infection
Item
active and uncontrolled infection
boolean
C0009450 (UMLS CUI [1])
uncontrolled medical problems unrelated to the malignancy that impair their ability to give informed consent or unacceptably reduce the safety of the proposed treatment
Item
uncontrolled medical problems unrelated to the malignancy that impair their ability to give informed consent or unacceptably reduce the safety of the proposed treatment
boolean
C0021430 (UMLS CUI [1,1])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
neurologic or psychiatric disorders that would interfere with informed consent or study follow-up
Item
neurologic or psychiatric disorders that would interfere with informed consent or study follow-up
boolean
C0021430 (UMLS CUI [1,1])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
known or suspected intolerance or hypersensitivity to the investigational new drug or closely related compounds like lamivudine, and/or a recent history of alcohol or other substance abuse
Item
known or suspected intolerance or hypersensitivity to the investigational new drug or closely related compounds like lamivudine, and/or a recent history of alcohol or other substance abuse.
boolean
C0020517 (UMLS CUI [1,1])
C0877874 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0209738 (UMLS CUI [2,2])
C0038586 (UMLS CUI [3])
C0877874 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0209738 (UMLS CUI [2,2])
C0038586 (UMLS CUI [3])
subjects who have used another investigational agent or participated in a clinical trial
Item
also not eligible are subjects who have used another investigational agent or participated in a clinical trial within the last 14 days prior to enrollment.
boolean
C2348568 (UMLS CUI [1])
pregnancy
Item
females with a positive pregnancy test at screening or subjects that have previously been enrolled into this study and subsequently withdrew.
boolean
C0032961 (UMLS CUI [1])